16.79
+1.86
+(12.46%)
At close: April 15 at 9:27:56 PM GMT+2
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in SEK | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 6 | 6 |
Avg. Estimate | 1.32B | 325.31M | 2.04B | 1.62B |
Low Estimate | 1.21B | 128M | 1.98B | 1.03B |
High Estimate | 1.44B | 478.93M | 2.15B | 2.01B |
Year Ago Sales | 29.64M | 49.84M | 257.35M | 2.04B |
Sales Growth (year/est) | 4,366.37% | 552.66% | 694.05% | -20.85% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
B9A.F | -- | -- | -- | -- |
S&P 500 | 6.76% | 5.73% | 9.19% | 14.14% |
Related Tickers
RPD.MU Royalty Pharma plc
28.20
0.00%
HQ1.MU Oruka Therapeutics Inc. R
7.05
+6.02%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
PROT Proteonomix, Inc.
0.0000
0.00%
7PO.F Poxel S.A.
0.4510
-11.39%
05Y.MU Vivoryon Therapeutics NV
1.7440
-4.49%
P0F.F Egetis Therapeutics AB (publ)
0.2955
-4.68%
ICY.HA Incyte Corp
52.14
+1.76%
BT3.BE Lineage Cell Therapeutics Inc
0.3800
-5.47%
2HA.F Spero Therapeutics, Inc.
0.6170
+16.64%